Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-30

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to evaluate the benefits, documented in experimental settings, of treatment with SGLT2-i in subjects with type 2 diabetes and older than 70 years in normal clinical practice.

The type of study does not involve immediate risks or direct benefits for the subjects taking part in it. The potential benefits for clinicians and healthcare systems are: greater knowledge of diabetic disease and the study of new treatment options. However, the analysis of the data will allow us to better identify which patients benefit most from treatment with glycosurics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers

NCT05408936

Diabetes Mellitus, Type 2

ACTIVE_NOT_RECRUITING

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

NCT04796428

Diabetes Mellitus, Type 2

UNKNOWN PHASE4

The Effects of Dapagliflozin in Normal Clinical Practice in T2D

NCT05418946

Type 2 Diabetes

UNKNOWN

Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients

NCT05914857

Prediabetic State Impaired Fasting Glucose Impaired Glucose Tolerance

NOT_YET_RECRUITING PHASE2

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

NCT00495469

Diabetes Mellitus, Type 2

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) may have important benefits for the elderly with type 2 diabetes (T2D), however some safety concerns still limit their use in patients over 70 years of age. The SOLD study (SGLT2-i in Older Diabetic patients) aim to evaluate which basal characteristics of the patients are more frequently related to the suspension of treatment with SGLT2-i in a real-life setting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type2Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SGLT2 inhibitor

Selective inhibitors of the sodium and glucose co-transporter 2 (SGLT2) originated as antidiabetic drugs thanks to their hypoglycemic and glycosuric effect.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Jardiance Synjardy Forxiga Xigduo Invokana Vokanamet Steglatro Segluromet

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent issued before any other activity related to the study (i.e. any activity related to data collection according to the study protocol);
* Diagnosis of type II diabetes mellitus, according to ADA indications for at least 3 months
* Males or females \> 70 years old
* Stable therapy for at least 3 months with oral hypoglycemic agents / insulin
* Prescription of SGLT2 inhibitors, in accordance with normal clinical practice and local drug prescription / reimbursement guidelines.

Exclusion Criteria

* Mental incapacity, unavailability or language barriers that preclude adequate understanding or cooperation;
* Diagnosis of type 1 diabetes mellitus, MODY (maturity-onset diabetes of the young), LADA (latent autoimmune diabetes in adults), gestational diabetes mellitus, secondary diabetes mellitus or any other hyperglycemic state other than T2D;
* Previous participation in the study. Participation is defined by having given informed consent to the study;
* Participation in another clinical study on T2D that includes any clinical intervention or administration of an investigational drug within 3 months prior to enrollment in the study

Minimum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No